Clean Science Q1FY27: Consol revenue up 10.5%, PAT +4.7%

Key takeaway from Q1FY27 numbers

Clean Science & Technology Ltd reported a mixed set of Q1FY27 results, with standalone performance softening while consolidated numbers improved. For the quarter ended June 30, 2026, standalone profit after tax (PAT) declined 4.3% year-on-year to ₹73.29 crore, alongside a 5.8% fall in standalone revenue from operations to ₹207.10 crore. In contrast, consolidated PAT rose 4.7% to ₹73.35 crore, supported by a 10.5% increase in consolidated revenue from operations to ₹268.43 crore.

The results were approved by the Board of Directors on August 1, 2026, after a limited review by statutory auditors Price Waterhouse Chartered Accountants LLP. Alongside earnings, the company also announced corporate actions and strategic steps, including a final dividend declaration, changes at the board level, and a new overseas subsidiary plan.

Standalone Q1FY27: revenue and profit slipped year-on-year

On a standalone basis, Clean Science reported revenue from operations of ₹207.10 crore in Q1FY27, down from ₹219.91 crore in Q1FY26. Profit before tax (PBT) came in at ₹97.52 crore versus ₹102.41 crore a year earlier, a 4.8% decline.

Standalone PAT stood at ₹73.29 crore compared with ₹76.57 crore in the year-ago quarter. The basic earnings per share (EPS) declined to ₹6.90 from ₹7.21, tracking the fall in standalone profit.

These standalone numbers indicate a weaker year-on-year quarter on both the top line and the bottom line. The filing provided the quarter’s financial metrics, but no detailed management commentary was included in the provided text.

Consolidated Q1FY27: growth supported by higher revenue

Consolidated performance was stronger than standalone results. Consolidated revenue from operations increased 10.5% to ₹268.43 crore from ₹242.87 crore in Q1FY26. Consolidated PBT rose 3.2% to ₹97.55 crore from ₹94.55 crore.

Consolidated PAT increased to ₹73.35 crore from ₹70.06 crore, up 4.7% year-on-year. Consolidated basic EPS improved to ₹6.90 from ₹6.59.

The divergence between standalone and consolidated outcomes is a key feature of the quarter. Investors typically track this gap to understand how subsidiaries and other consolidated entities are contributing to reported earnings.

Snapshot table: Q1FY27 vs Q1FY26 (₹ crore)

Board actions: results approval, dividend, and director appointment

The Board approved the unaudited standalone and consolidated financial results on August 1, 2026. The company stated that the results were subject to a limited review by Price Waterhouse Chartered Accountants LLP.

Clean Science also declared a final dividend for FY2025-26. The dividend is payable on September 30, 2026, to shareholders on the register as of September 5, 2026.

Separately, the Board co-opted Krishnakumar Satyanarain Saboo as an Additional Director, as reported in the provided text.

Overseas expansion step: Netherlands subsidiary plan

The company also disclosed that the Board approved the incorporation of a wholly-owned foreign subsidiary in the Netherlands by Clean Fino-Chem Limited. The purpose mentioned was specialty chemical distribution.

For investors, a distribution-led subsidiary in Europe can be a signal of a structured approach to international sales and customer servicing. The text does not provide timelines, capital allocation, or expected financial impact from this incorporation.

Five-year supply agreement with Kemin Industries

On August 1, 2026, Clean Science announced a five-year strategic supply agreement with Kemin Industries. The company stated it would provide key ingredients for the food and feed industry.

The agreement is effective from August 1, 2026, and positions Clean Science as a substantial primary supplier for Kemin. As described, the arrangement is intended to improve long-term revenue visibility and operational stability, aligning with the company’s broader business strategy.

Market context: FY26 was a weaker year

The quarter’s mixed trend follows a softer FY26 on profitability. Clean Science reported a 14% decline in FY26 standalone PAT to ₹251 crore, while standalone revenue from operations declined to ₹815 crore from ₹922 crore in FY25.

On a consolidated basis for FY26, revenue from operations was ₹957 crore compared with ₹967 crore in FY25. Consolidated PAT declined 13% to ₹230 crore from ₹266 crore. Consolidated EBITDA was reported at ₹355 crore with margins of 37.7%, compared with ₹388 crore and 40.8% in the prior year.

The FY26 disclosures also included a recommended final dividend of ₹4 per equity share of face value ₹1 each, subject to shareholder approval at the ensuing Annual General Meeting, and an additional investment approval of ₹200 crore in Clean Fino-Chem Limited.

What investors may track after this update

With Q1FY27 showing lower standalone revenue and profit but higher consolidated revenue and PAT, investors will likely focus on how subsidiary operations and overseas initiatives are influencing consolidated performance. The Netherlands subsidiary and the Kemin supply agreement are relevant in that context, but the provided text does not quantify near-term revenue contribution.

In market data cited in the provided content, a current share price of ₹802.75 was listed. Separately, the stock was stated to have closed at ₹817.10 on May 12, 2026 (NSE), with returns of -11.28% over six months and -35.31% over 12 months.

Company identifiers and registered location

Clean Science & Technology Limited’s BSE scrip code was referenced as 543318. The corporate address listed in the provided text includes Magarpatta City, Hadapsar, Pune, Maharashtra 411013.

Conclusion

Clean Science’s Q1FY27 results highlight a decline in standalone revenue and profit, while consolidated revenue and PAT rose year-on-year. The Board’s August 1, 2026 actions included approving the quarterly results, declaring a FY2025-26 final dividend with specified record and payment dates, appointing an Additional Director, and approving a Netherlands subsidiary for distribution. The five-year supply agreement with Kemin Industries, effective August 1, 2026, is the next confirmed operational milestone that investors can track for execution and visibility.